Döri, Ferenc; Arweiler, Nicole B.; Szántó, Erika; Ágics, Anikó; Gera, István; Sculean, Anton (2013). Ten-year results following treatment of intrabony defects with an enamel matrix protein derivative combined with either a natural bone mineral or a β-tricalcium phosphate. Journal of periodontology, 84(6), pp. 749-757. American Academy of Periodontology 10.1902/jop.2012.120238
Text
JPerio.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (527kB) |
BACKGROUND
The purpose of the present study is to evaluate the 10-year results following treatment of intrabony defects treated with an enamel matrix protein derivative (EMD) combined with either a natural bone mineral (NBM) or β-tricalcium phosphate (β-TCP).
METHODS
Twenty-two patients with advanced chronic periodontitis and displaying one deep intrabony defect were randomly treated with a combination of either EMD + NBM or EMD + β-TCP. Clinical evaluations were performed at baseline and at 1 and 10 years. The following parameters were evaluated: plaque index, bleeding on probing, probing depth, gingival recession, and clinical attachment level (CAL). The primary outcome variable was CAL.
RESULTS
The defects treated with EMD + NBM demonstrated a mean CAL change from 8.9 ± 1.5 mm to 5.3 ± 0.9 mm (P <0.001) and to 5.8 ± 1.1 mm (P <0.001) at 1 and 10 years, respectively. The sites treated with EMD + β-TCP showed a mean CAL change from 9.1 ± 1.6 mm to 5.4 ± 1.1 mm (P <0.001) at 1 year and 6.1 ± 1.4 mm (P <0.001) at 10 years. At 10 years two defects in the EMD + NBM group had lost 2 mm, whereas two other defects had lost 1 mm of the CAL gained at 1 year. In the EMD + β-TCP group three defects had lost 2 mm, whereas two other defects had lost 1 mm of the CAL gained at 1 year. Compared with baseline, at 10 years, a CAL gain of ≥3 mm was measured in 64% (i.e., seven of 11) of the defects in the EMD + NBM group and in 82% (i.e., nine of 11) of the defects in the EMD + β-TCP group. No statistically significant differences were found between the 1- and 10-year values in either of the two groups. Between the treatment groups, no statistically significant differences in any of the investigated parameters were observed at 1 and 10 years.
CONCLUSION
Within their limitations, the present findings indicate that the clinical improvements obtained with regenerative surgery using EMD + NBM or EMD + β-TCP can be maintained over a period of 10 years.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > School of Dental Medicine > Department of Periodontology |
UniBE Contributor: |
Sculean, Anton |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0022-3492 |
Publisher: |
American Academy of Periodontology |
Language: |
English |
Submitter: |
Eveline Carmen Schuler |
Date Deposited: |
25 Feb 2014 10:31 |
Last Modified: |
05 Dec 2022 14:27 |
Publisher DOI: |
10.1902/jop.2012.120238 |
PubMed ID: |
22873657 |
Uncontrolled Keywords: |
Bone grafting, enamel matrix proteins, periodontitis, randomized controlled trial, regenerative medicine |
BORIS DOI: |
10.7892/boris.40638 |
URI: |
https://boris.unibe.ch/id/eprint/40638 |